Introduction
The rapid growth of telehealth ketamine services -- companies and clinics offering at-home oral or sublingual ketamine treatment initiated and managed via telemedicine -- has created a new and complex regulatory landscape at the intersection of FDA drug regulation, DEA controlled substance law, state medical practice acts, and Federal Trade Commission (FTC) advertising enforcement. For clinicians, practice managers, and compliance officers involved in these services, understanding the boundaries of permissible marketing is not merely a legal nicety but a prerequisite for sustainable practice operation.
This article reviews the current regulatory framework governing the marketing and advertising of telehealth ketamine therapy, identifies common compliance pitfalls, and provides actionable guidance for developing marketing materials that are both effective and legally defensible. While this article addresses the regulatory landscape as of mid-2025, this is a rapidly evolving area and practitioners should consult legal counsel for jurisdiction-specific guidance.
FDA Regulatory Framework
Off-Label Promotion Rules
Ketamine (racemic) is FDA-approved as an anesthetic agent. Its use for depression, anxiety, chronic pain, and other psychiatric or pain conditions is off-label. Esketamine (Spravato) is FDA-approved specifically for treatment-resistant depression and major depressive disorder with acute suicidal ideation or behavior, but only in the intranasal formulation administered under the REMS program.
The FDA's position on off-label promotion is well-established: manufacturers may not promote drugs for unapproved uses. However, this restriction applies to pharmaceutical manufacturers and their agents, not directly to individual prescribers. Clinicians may prescribe ketamine off-label based on their medical judgment, and they may discuss off-label uses with patients.
The gray area arises when clinicians or their practice entities engage in marketing that could be construed as promoting off-label use at scale. While a physician discussing off-label ketamine use with an individual patient during a clinical encounter is unambiguously permissible, a practice advertising "ketamine for depression" on a website or in paid search campaigns enters territory where FDA, FTC, and state regulatory oversight converge.
Substantiation Requirements
Marketing claims about ketamine's efficacy must be substantiated by competent and reliable scientific evidence. The FTC defines this standard as "tests, analyses, research, or studies that have been conducted and evaluated in an objective manner by qualified persons, that are generally accepted in the profession to yield accurate and reliable results." For ketamine, the substantial body of randomized controlled trial evidence supporting its antidepressant effects provides a reasonable substantiation basis for general claims about efficacy in depression.
However, specific claims require specific evidence. Statements such as "ketamine cures depression," "guaranteed results," or "works when nothing else has" are likely unsubstantiated and misleading. Even claims supported by clinical evidence should be stated with appropriate qualification: "ketamine has shown rapid antidepressant effects in clinical studies" is defensible; "ketamine will relieve your depression" is not.
Distinguishing Esketamine From Racemic Ketamine
Marketing materials must clearly distinguish between FDA-approved esketamine (Spravato) and off-label racemic ketamine. Practices offering racemic ketamine should not imply FDA approval for psychiatric indications. Conversely, practices administering esketamine under the REMS program may reference FDA approval but must accurately represent the specific approved indications, the REMS requirements, and the administration setting restrictions.
Conflating the two products in marketing -- for example, using FDA approval of esketamine to imply regulatory endorsement of at-home oral racemic ketamine -- is both misleading and potentially actionable under FTC and state consumer protection statutes.
DEA and Controlled Substance Considerations
Schedule III Classification
Ketamine is a Schedule III controlled substance under the Controlled Substances Act. This classification imposes specific requirements on prescribing, dispensing, record-keeping, and -- by extension -- how services involving ketamine can be marketed.
Marketing materials should not minimize or obscure ketamine's controlled substance status. References to ketamine therapy should acknowledge that it involves a prescription medication that requires a legitimate prescriber-patient relationship, medical evaluation, and ongoing monitoring. Framing ketamine as a casual wellness product or lifestyle enhancement misrepresents the clinical nature of the treatment and the regulatory obligations attending its prescription.
The Ryan Haight Act
The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 requires that at least one in-person medical evaluation occur before a controlled substance can be prescribed via telemedicine, with certain exceptions. During the COVID-19 public health emergency, the DEA implemented temporary flexibilities allowing the initiation of controlled substance prescriptions via telemedicine without a prior in-person visit.
As of 2025, the DEA has proposed and implemented rules to formalize post-pandemic telemedicine prescribing of controlled substances. The specifics of these rules -- including whether an initial telemedicine-only encounter is sufficient for ketamine prescribing -- directly affect how telehealth ketamine services can be structured and marketed. Practices must ensure their marketing accurately reflects the current DEA requirements in their jurisdiction rather than relying on pandemic-era flexibilities that may have expired or been modified.
State-Level Prescribing Restrictions
Several states have enacted or proposed legislation specifically addressing telehealth prescribing of ketamine, ranging from requirements for initial in-person evaluation to mandated supervision protocols for at-home administration. Marketing materials for telehealth ketamine services must comply with the specific requirements of each state in which the practice operates. National advertising campaigns must either comply with the most restrictive applicable state law or include appropriate geographic disclaimers.
FTC Advertising Enforcement
Health Claims Standards
The FTC has authority over advertising claims for health-related services and has been increasingly active in enforcing standards for mental health treatment marketing. FTC enforcement actions have targeted companies making unsubstantiated claims about depression treatments, anxiety therapies, and other mental health interventions.
Key FTC principles applicable to ketamine marketing include the following:
Truthfulness. All claims must be truthful and not misleading. This includes both explicit claims and net impressions -- the overall message a reasonable consumer would take from the advertising, including visual elements, testimonials, and implied claims.
Substantiation. Health claims must be supported by competent and reliable scientific evidence before they are made, not after an enforcement action.
Disclosure of material information. Material facts that would affect a consumer's decision must be disclosed. For ketamine therapy, this includes the off-label nature of treatment (for racemic ketamine), the controlled substance classification, the need for medical supervision, potential side effects, and the fact that not all patients respond.
Testimonials. Patient testimonials must reflect typical results, or the advertising must clearly disclose what results are typical. A testimonial from a patient who experienced dramatic improvement is misleading if most patients experience more modest results, unless accompanied by a clear disclosure such as "results vary; not all patients respond to treatment."
Recent Enforcement Trends
The FTC has signaled increased scrutiny of digital health companies, including telemedicine platforms. Recent enforcement actions have targeted companies for misleading claims about treatment efficacy, failure to disclose material risks, deceptive use of clinical data (such as cherry-picking favorable study results), and inadequate disclosures about subscription auto-renewal terms. Telehealth ketamine providers, many of which rely heavily on digital marketing and direct-to-consumer advertising, should anticipate continued regulatory attention.
State Medical Board Considerations
Advertising Standards for Medical Practices
State medical boards regulate physician advertising through medical practice acts and associated regulations. While specific provisions vary by state, common principles include the following: advertising must not be false, misleading, or deceptive; claims of superiority over other treatments must be substantiated; use of the term "board certified" must be accurate and refer to a recognized certifying body; and advertising must not create unjustified expectations of treatment outcomes.
Telemedicine-Specific Requirements
Many states have enacted telemedicine-specific regulations that affect marketing. Some states require that telemedicine advertisements disclose the provider's physical location and licensing state. Others mandate specific informed consent language that must precede any telehealth encounter. Practices operating across multiple states must ensure their marketing complies with each state's requirements, which may necessitate state-specific landing pages or disclaimers.
Common Compliance Pitfalls
Overstating Efficacy
The most frequent compliance failure in ketamine marketing is overstating efficacy. Claims such as "breakthrough cure for depression," "works in hours when other treatments take weeks," or "80 percent success rate" are problematic because they may imply guaranteed results or cherry-pick favorable statistics without context. Evidence-based alternative language might state: "Ketamine has demonstrated rapid-onset antidepressant effects in clinical studies of treatment-resistant depression. Individual results vary, and ketamine is not effective for all patients."
Minimizing Risks
Marketing materials that emphasize ketamine's benefits while minimizing or omitting its risks create a misleading net impression. The dissociative effects, cardiovascular changes, abuse potential, and need for medical monitoring are material facts that should be included in marketing materials, even in abbreviated formats such as social media posts that link to more complete risk information.
Misleading Comparisons
Comparisons to other treatments (such as "unlike traditional antidepressants, ketamine works immediately") must be accurate and not misleading in context. While ketamine does have a faster onset of action than SSRIs, framing this comparison in a way that implies SSRIs are ineffective or that ketamine is universally superior misrepresents the clinical evidence.
Implied FDA Approval
Any marketing language that could lead a reasonable consumer to believe that at-home oral ketamine is FDA-approved for depression or other psychiatric conditions is misleading. This includes using the Spravato REMS approval to lend credibility to a different product (racemic ketamine) administered by a different route (oral) in a different setting (at home). These are materially different treatments with different regulatory statuses.
Celebrity Endorsements and Social Media
The use of celebrity endorsements and influencer marketing for ketamine therapy raises additional compliance issues. FTC guidelines require clear disclosure of material connections between endorsers and the service being promoted. Health-related endorsements carry heightened scrutiny, and testimonials about specific health outcomes from ketamine must meet the substantiation and typicality requirements discussed above.
Building a Compliant Marketing Program
Content Review Process
Establish a formal review process for all marketing materials before publication. This process should involve clinical review (to ensure medical accuracy), legal review (to ensure regulatory compliance), and compliance review (to check against FTC, FDA, DEA, and state-specific requirements). Document the review process for each piece of marketing content.
Substantiation Files
Maintain a substantiation file containing the clinical evidence supporting each marketing claim. This file should be compiled before claims are made, not retroactively. For ketamine, relevant substantiation includes published randomized controlled trials, systematic reviews, meta-analyses, and professional society guidelines.
Required Disclosures
Develop standard disclosure language for common marketing contexts:
Website pages: Include a prominent disclosure that racemic ketamine for depression, anxiety, and pain is prescribed off-label; that ketamine is a Schedule III controlled substance; that treatment requires medical evaluation and monitoring; and that results vary among patients.
Social media posts: Include a link to full risk and disclosure information. Use concise but accurate language about the treatment. Avoid before-and-after claims without appropriate context.
Paid search advertising: Ensure ad copy and landing pages are consistent. Do not make claims in ad headlines that are contradicted or qualified on the landing page.
Training and Documentation
Train all staff involved in marketing, sales, and patient communication on compliance requirements. Document this training. Establish a process for reporting and addressing potential compliance issues before they result in regulatory action.
Esketamine Practice Management Considerations
REMS Compliance in Marketing
Practices offering FDA-approved esketamine (Spravato) under the REMS program have specific marketing considerations. Marketing materials may reference FDA approval for treatment-resistant depression but must accurately represent the REMS requirements: administration in a certified healthcare setting, post-administration monitoring for a minimum of two hours, and the restriction that patients may not take the drug home.
Marketing that implies esketamine can be self-administered at home or that minimizes the REMS monitoring requirements is both misleading and a potential REMS violation.
Dual-Track Services
Some practices offer both REMS-compliant esketamine and off-label racemic ketamine. Marketing for these practices must clearly distinguish between the two services, their different regulatory statuses, and their different administration settings. A single marketing message that blends information about both products risks confusing consumers and regulators.
Looking Ahead
The regulatory environment for telehealth ketamine services continues to evolve. Anticipated developments include finalization of DEA telemedicine prescribing rules post-pandemic, potential FDA regulatory guidance specifically addressing off-label promotion by telehealth platforms, increased FTC enforcement activity targeting digital health advertising, and possible state legislation creating ketamine-specific telehealth frameworks.
Practices that invest in compliance infrastructure now -- including substantiation files, legal review processes, and staff training -- will be better positioned to adapt to regulatory changes and to avoid enforcement actions that could threaten practice viability.
References
- FDA: Understanding Unapproved Use of Approved Drugs ("Off Label") — FDA guidance on the regulatory framework for off-label drug use and promotion
- DEA: Ryan Haight Online Pharmacy Consumer Protection Act — DEA final rule implementing telemedicine prescribing requirements for controlled substances
- FTC: Health Products Compliance Guidance — Federal Trade Commission guidance on substantiation requirements for health-related advertising claims
- PubMed: Ethical and Regulatory Considerations for At-Home Ketamine Treatment (Wilkinson et al., 2022) — Expert analysis of the ethical and regulatory challenges in telehealth ketamine prescribing
- FDA: Spravato REMS Program Requirements — Official REMS program documentation including healthcare setting certification and monitoring requirements
- NIH: Telemedicine and Prescribing Controlled Substances — National Institutes of Health resource on evolving telemedicine regulatory frameworks
Share